

MEDIAN Technologies lists on NYSE Alternext

Paris, 20 May 2011 – NYSE Euronext today announced the listing of MEDIAN Technologies, a provider of software and services specialized in clinical and diagnostic applications that use medical imaging in oncology, on NYSE Alternext in Paris.

Founded in 2002, MEDIAN Technologies is a software developer and service provider, specialized in clinical solutions that make use of medical imaging. Its applications help radiologists, oncologists, and more generally all specialists who prescribe radiological exams to read, detect, quantify and track test results. The company has a staff of 40, more than half of whom work in R&D, and has a subsidiary in the USA.

MEDIAN Technologies (ticker code: ALMDT) was listed through admission to trading of 5,588,838 existing shares including 1,239,356 new shares issued in a private offering to qualified investors. The total amount raised was €9.98 million.

The admission and issue price of MEDIAN Technologies shares was set at €8.05. Market capitalization stood at €45 million on the day of listing.

“We are very pleased to welcome MEDIAN Technologies to NYSE Alternext. MEDIAN Technologies is an innovative company that understands the pharmaceutical industry’s need for better diagnostics and tracking of patients with serious illnesses,” said Ronald Kent, Group Executive Vice President and head of international listings at NYSE Euronext. *“By making the strategic decision to undertake an IPO, MEDIAN Technologies will increase its visibility and facilitate future growth.”*

Fredrik Brag, Chairman and CEO of MEDIAN Technologies, added, *“We have developed an innovative solution for oncology imaging analysis. The system is particularly well suited to resolving the issues encountered in clinical trials and has already been adopted by three of the largest pharma companies. The recent round of fundraising and today’s IPO will provide the necessary financing for the commercialization of our solutions and services and I wish to thank the investors who have provided us with their support.”*

In six years, 165 companies from Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US have raised €2.4 billion on NYSE Alternext, half of this through secondary issues. Their combined market capitalization totals €5.6 billion.

Contacts:

NYSE Euronext – Press relations

Caroline Tourrier: +33 (0)1 49 27 10 82

ALIZE RP – Press relations

Caroline Carmagnol: +33 (0)1 42 68 86 43



About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets – the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca – represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the Fortune 500. For more information, please visit: www.nyx.com.

About MEDIAN Technologies

MEDIAN Technologies was founded in 2002 by Fredrik Brag (the current Chairman and CEO), Gérard Milhiet and Arnaud Butzbach. It is based at Sophia Antipolis (in the south of France) and has a subsidiary in the USA. The company currently has a staff of 40, over half of whom work in R&D.

MEDIAN Technologies offers solutions and services for diagnosing and monitoring cancer patients. It targets both the oncology clinical trials market (its prime market) and the patient care market.

MEDIAN Technologies collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Automation (INRIA), University of Chicago and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN Technologies has been present in the market since 2007 through direct sales of its lesion management solutions and alliances with specialist cancer centers in Europe and the USA.

Since its incorporation, the company has raised about €16 million in three rounds of financing (in 2003, 2004 and 2006-07) with prestigious international investors, including Draper Fisher Jurvetson ePlanet Ventures (DFJ) (USA), Idinvest Partners / AGF Private Equity (France), Auriga Partners (France) and the University of Chicago Hospitals (USA). MEDIAN Technologies also benefited from €2.9 million in financial support awarded to its LESIO project by OSEO (the French state innovation agency) over the period 2008-10 and has been accredited as an "innovative company" by the agency. For more information about MEDIAN, please visit www.mediantechologies.com.